Patents by Inventor William Maton
William Maton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11078163Abstract: The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa? with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa? and wherein the compound substituents are as defined herein.Type: GrantFiled: July 16, 2019Date of Patent: August 3, 2021Assignee: BIAL-PORTELA & Cª, S.A.Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
-
Patent number: 11046654Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: GrantFiled: July 9, 2018Date of Patent: June 29, 2021Assignee: BIAL-PORTELA & CA, S.A.Inventors: Carla Patricia da Costa Pereira Rosa, Rita Gusmao De Noronha, Laszlo Erno Kiss, Patricio Manuel Vieira Araujo Soares Da Silva, Domenico Russo, Jorge Bruno Reis Wahnon, William Maton
-
Publication number: 20200140391Abstract: The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa? with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa? and wherein the compound substituents are as defined herein.Type: ApplicationFiled: July 16, 2019Publication date: May 7, 2020Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
-
Patent number: 10329268Abstract: The present invention provides a compound of formula N wherein: X is CH2, oxygen or sulphur; R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group, wherein N is in the form of the individual R- and S-enantiomer or a mixture of the (R)- and (S)-enantiomer. The present invention also provides a compound of formula MA. The present invention also provides processes for preparing the above compounds, and processes involving their use. The compounds are particularly useful as intermediates in the synthesis of peripherally-selective inhibitors of dopamine-?-hydroxylase.Type: GrantFiled: September 12, 2014Date of Patent: June 25, 2019Assignee: Bial-Portela & CA, S.A.Inventors: Domenico Russo, Jorge Wahnon, William Maton, Beat T. Weber, Paula Jeronimo, Luisa Sousa, Pedro Barrocas, Rita Pires, Ricardo Lima, Teofilo Vasconcelos
-
Publication number: 20190135764Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: ApplicationFiled: July 9, 2018Publication date: May 9, 2019Inventors: Carla Patricia da Costa Pereira ROSA, Rita GUSMAO DE NORONHA, Laszlo Erno KISS, Patricio Manuel Vieira Araujo SOARES DA SILVA, Domenico RUSSO, Jorge Bruno Reis WAHNON, William MATON
-
Patent number: 10059696Abstract: The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.Type: GrantFiled: February 23, 2016Date of Patent: August 28, 2018Assignee: Bial-Portela & CA, S.A.Inventors: Alexander Beliaev, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Jonathan Madec, Jean-Marie Schneider, William Maton
-
Patent number: 10023541Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: GrantFiled: December 19, 2016Date of Patent: July 17, 2018Assignee: BIAL-PORTELA & Ca, S.A.Inventors: Carla Patricia da Costa Pereira Rosa, Rita Gusmao De Noronha, Laszlo Erno Kiss, Patricio Manuel Vieira Araujo Soares Da Silva, Domenico Russo, Jorge Bruno Reis Wahnon, William Maton
-
Publication number: 20170101381Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: ApplicationFiled: December 19, 2016Publication date: April 13, 2017Inventors: Carla Patricia da Costa Pereira ROSA, Rita GUSMAO DE NORONHA, Laszlo Erno KISS, Patricio Manuel Vieira Araujo SOARES DA SILVA, Domenico RUSSO, Jorge Bruno Reis WAHNON, William MATON
-
Patent number: 9549915Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: GrantFiled: July 24, 2013Date of Patent: January 24, 2017Assignee: BIAL-PORTELA & CA, S.A.Inventors: Carla Patricia da Costa Pereira Rosa, Rita Gusmao De Noronha, Laszlo Erno Kiss, Patricio Manuel Vieira Araujo Soares Da Silva, Domenico Russo, Jorge Bruno Reis Wahnon, William Maton
-
Publication number: 20170001962Abstract: The present invention concerns a process for preparing a compound having the Formula A: or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa?, with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa?, and wherein the compound substituents are as defined herein.Type: ApplicationFiled: January 23, 2015Publication date: January 5, 2017Applicant: BIAL-PORTELA & Cª, S.A.Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
-
Publication number: 20160311804Abstract: The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.Type: ApplicationFiled: February 23, 2016Publication date: October 27, 2016Inventors: Alexander BELIAEV, Jorge Bruno Reis WAHNON, David Alexander LEARMONTH, Jonathan MADEC, Jean-Marie SCHNEIDER, William MATON
-
Publication number: 20160221981Abstract: The present invention provides a compound of formula N wherein: X is CH2, oxygen or sulphur; R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group, wherein N is in the form of the individual R- and S-enantiomer or a mixture of the (R)- and (S)-enantiomer. The present invention also provides a compound of formula MA. The present invention also provides processes for preparing the above compounds, and processes involving their use. The compounds are particularly useful as intermediates in the synthesis of peripherally-selective inhibitors of dopamine-?-hydroxylase.Type: ApplicationFiled: September 12, 2014Publication date: August 4, 2016Inventors: Domenico RUSSO, Jorge WAHNON, William MATON, Beat T. WEBER, Paula JERÓNIMO, Luísa SOUSA, Pedro BARROCAS, Rita PIRES, Ricardo LIMA, Teófilo VASCONCELOS
-
Patent number: 9346751Abstract: The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.Type: GrantFiled: June 29, 2012Date of Patent: May 24, 2016Assignee: Bial-Portela & CA, S.A.Inventors: Alexander Beliaev, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Jonathan Madec, Jean-Marie Schneider, William Maton
-
Publication number: 20150197503Abstract: A process for preparing a substituted urea compound of Formula II or Formula I, or a pharmaceutically acceptable salt or ester thereof, Formula II, Formula I the process comprising the reaction of an intermediate of Formula II? or Formula 1?, Formula II?, Formula I? with a carbamoyl halide of the formula: R1R2NC(=0)Hal, in a solvent consisting essentially of pyridine, wherein Hal represents Cl, F, I or Br, and wherein ring A, and R1, R2, R5, V, W, X, Y and Z are as defined herein.Type: ApplicationFiled: July 26, 2013Publication date: July 16, 2015Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
-
Publication number: 20150174103Abstract: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.Type: ApplicationFiled: July 24, 2013Publication date: June 25, 2015Inventors: Carla Patricia da Costa Pereira Rosa, Rita Gusmao De Noronha, Laszlo Erno Kiss, Patricio Manuel Vieira Araujo Soares Da Silva, Domenico Russo, Jorge Bruno Reis Wahnon, William Maton
-
Publication number: 20140221668Abstract: The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.Type: ApplicationFiled: June 29, 2012Publication date: August 7, 2014Applicant: BIAL-PORTELA & CA, S.A.Inventors: Alexander Beliaev, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Jonathan Madec, Jean-Marie Schneider, William Maton